40+ min ago  (1034+ words) Just over a month ago, Revolution Medicines stunned the oncology space, revealing that its RAS inhibitor doubled survival in a Phase 3 trial for pancreatic cancer'a deadly malignancy with just a 13% five-year survival rate. Two weeks later, the good news continued…...

5+ hour, 52+ min ago  (223+ words) Bio Space The stock option has an exercise price equal to the closing price of the Company's Class A common stock on the Grant Date, and will vest over 4 years, with 25% of the underlying shares vesting on the one-year anniversary…...

6+ hour, 44+ min ago  (224+ words) Bio Space Gossamer Bio to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 18, 2026 SAN DIEGO--(BUSINESS WIRE)--$GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib…...

2+ hour, 45+ min ago  (1002+ words) Approved for use before surgery based on DESTINY-Breast11 Phase III trial Approved for use following surgery based on DESTINY-Breast05 Phase III trial Two new indications bring Astra Zeneca and Daiichi Sankyo's ENHERTU into curative-intent setting, reinforcing its role across stages…...

6+ hour, 27+ min ago  (666+ words) WHIPPANY, N. J. --(BUSINESS WIRE)--New data from the Phase II ARASEC trial show NUBEQA" (darolutamide) plus androgen deprivation therapy (ADT) resulted in a 71% reduction in the risk of progression or death per CHAARTED criteria compared to ADT alone (HR 0. 29; 95% CI 0. 200. 40; P…...

2+ hour, 43+ min ago  (317+ words) The findings " presented at the 2026 American Urological Association (AUA) Annual Meeting and scheduled for publication in Translational Andrology and Urology later in May " reflect outcomes observed following a re-induction dose (second dose overall) of ADSTILADRIN in a real-world clinical setting,…...

2+ hour, 45+ min ago  (837+ words) TOKYO--(BUSINESS WIRE)--Enhertu" (fam-trastuzumab deruxtecan-nxki) has been approved by the U. S. Food and Drug Administration (FDA) for two new breast cancer indications in the neoadjuvant and adjuvant settings of patients with HER2 positive early breast cancer. Enhertu is a specifically engineered…...

2+ hour, 51+ min ago  (793+ words) Last month, the FDA approved Regeneron Pharmaceuticals" Otarmeni for a specific type of hearing loss, validating the concept of genetic medicines. As these medicines continue to advance, countless more conditions stand to benefit from the approach. Researchers are taking note....

2+ hour, 53+ min ago  (787+ words) Bio Space Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - Published prospective cohort showed durable responses and manageable safety in patients with HCC following prior immunotherapy - Median overall survival of 12. 3 months in…...

6+ hour, 25+ min ago  (699+ words) Bio Space Signatera" CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC) Marks the first FDA-approved use of personalized molecular residual disease (MRD) testing to guide treatment decisions Solidifies Natera's Treatment on MRD (TOMR) approach…...